These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 16498575

  • 1. Agreement and validity of pharmacy data versus self-report for use of osteoporosis medications among chronic glucocorticoid users.
    Curtis JR, Westfall AO, Allison J, Freeman A, Kovac SH, Saag KG.
    Pharmacoepidemiol Drug Saf; 2006 Oct; 15(10):710-8. PubMed ID: 16498575
    [Abstract] [Full Text] [Related]

  • 2. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.
    Cramer JA, Amonkar MM, Hebborn A, Altman R.
    Curr Med Res Opin; 2005 Sep; 21(9):1453-60. PubMed ID: 16197664
    [Abstract] [Full Text] [Related]

  • 3. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
    Penning-van Beest FJ, Goettsch WG, Erkens JA, Herings RM.
    Clin Ther; 2006 Feb; 28(2):236-42. PubMed ID: 16678644
    [Abstract] [Full Text] [Related]

  • 4. Prescriptions for vitamin D among patients taking antiresorptive agents in Canada.
    Hanley DA, Zhang Q, Meilleur MC, Mavros P, Sen SS.
    Curr Med Res Opin; 2007 Jun; 23(6):1473-80. PubMed ID: 17559742
    [Abstract] [Full Text] [Related]

  • 5. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates.
    McHorney CA, Schousboe JT, Cline RR, Weiss TW.
    Curr Med Res Opin; 2007 Dec; 23(12):3137-52. PubMed ID: 17988435
    [Abstract] [Full Text] [Related]

  • 6. Prevalence and determinants of osteoporosis drug prescription among patients with high exposure to glucocorticoid drugs.
    Ettinger B, Chidambaran P, Pressman A.
    Am J Manag Care; 2001 Jun; 7(6):597-605. PubMed ID: 11439733
    [Abstract] [Full Text] [Related]

  • 7. Prevalence of evaluation and treatment of glucocorticoid-induced osteoporosis in men.
    Cruse LM, Valeriano J, Vasey FB, Carter JD.
    J Clin Rheumatol; 2006 Oct; 12(5):221-5. PubMed ID: 17023807
    [Abstract] [Full Text] [Related]

  • 8. Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users.
    Curtis JR, Westfall AO, Allison JJ, Freeman A, Saag KG.
    Osteoporos Int; 2006 Oct; 17(8):1268-74. PubMed ID: 16724286
    [Abstract] [Full Text] [Related]

  • 9. Challenges in improving the quality of osteoporosis care for long-term glucocorticoid users: a prospective randomized trial.
    Curtis JR, Westfall AO, Allison J, Becker A, Melton ME, Freeman A, Kiefe CI, MacArthur M, Ockershausen T, Stewart E, Weissman N, Saag KG.
    Arch Intern Med; 2007 Mar 26; 167(6):591-6. PubMed ID: 17389291
    [Abstract] [Full Text] [Related]

  • 10. Self-reported information and pharmacy claims were comparable for lipid-lowering medication exposure.
    Brown DW, Anda RF, Felitti VJ.
    J Clin Epidemiol; 2007 May 26; 60(5):525-9. PubMed ID: 17419964
    [Abstract] [Full Text] [Related]

  • 11. Reliability of Group Health Cooperative automated pharmacy data by drug benefit status.
    Boudreau DM, Doescher MP, Saver BG, Jackson JE, Fishman PA.
    Pharmacoepidemiol Drug Saf; 2005 Dec 26; 14(12):877-84. PubMed ID: 15931653
    [Abstract] [Full Text] [Related]

  • 12. Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting.
    Downey TW, Foltz SH, Boccuzzi SJ, Omar MA, Kahler KH.
    South Med J; 2006 Jun 26; 99(6):570-5. PubMed ID: 16800411
    [Abstract] [Full Text] [Related]

  • 13. Factors contributing to compliance with osteoporosis medication.
    Kertes J, Dushenat M, Vesterman JL, Lemberger J, Bregman J, Friedman N.
    Isr Med Assoc J; 2008 Mar 26; 10(3):207-13. PubMed ID: 18494234
    [Abstract] [Full Text] [Related]

  • 14. Measures of adherence based on self-report exhibited poor agreement with those based on pharmacy records.
    Guénette L, Moisan J, Préville M, Boyer R.
    J Clin Epidemiol; 2005 Sep 26; 58(9):924-33. PubMed ID: 16085196
    [Abstract] [Full Text] [Related]

  • 15. How well do patients report noncompliance with antihypertensive medications?: a comparison of self-report versus filled prescriptions.
    Wang PS, Benner JS, Glynn RJ, Winkelmayer WC, Mogun H, Avorn J.
    Pharmacoepidemiol Drug Saf; 2004 Jan 26; 13(1):11-9. PubMed ID: 14971118
    [Abstract] [Full Text] [Related]

  • 16. Compliance with osteoporosis medications.
    Solomon DH, Avorn J, Katz JN, Finkelstein JS, Arnold M, Polinski JM, Brookhart MA.
    Arch Intern Med; 2005 Nov 14; 165(20):2414-9. PubMed ID: 16287772
    [Abstract] [Full Text] [Related]

  • 17. Relationships between multiple self-reported nonadherence measures and pharmacy records.
    Rickles NM, Svarstad BL.
    Res Social Adm Pharm; 2007 Dec 14; 3(4):363-77. PubMed ID: 18082873
    [Abstract] [Full Text] [Related]

  • 18. Consequences of poor compliance with bisphosphonates.
    Briesacher BA, Andrade SE, Yood RA, Kahler KH.
    Bone; 2007 Nov 14; 41(5):882-7. PubMed ID: 17707710
    [Abstract] [Full Text] [Related]

  • 19. Are patients reliable when self-reporting medication use? Validation of structured drug interviews and home visits by drug analysis and prescription data in acutely hospitalized patients.
    Glintborg B, Hillestrøm PR, Olsen LH, Dalhoff KP, Poulsen HE.
    J Clin Pharmacol; 2007 Nov 14; 47(11):1440-9. PubMed ID: 17962430
    [Abstract] [Full Text] [Related]

  • 20. Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance.
    Brookhart MA, Avorn J, Katz JN, Finkelstein JS, Arnold M, Polinski JM, Patrick AR, Mogun H, Solmon DH.
    Am J Med; 2007 Mar 14; 120(3):251-6. PubMed ID: 17349448
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.